115 Potential Immunological Triggers for Central Disorders of Hypersomnolence Appendix B Results excluding people with a clinical diagnosis Below we repeated the analyses excluding those with a clinical hypersomnolence diagnosis that was not fully compliant with the ICSD-3 criteria. For narcolepsy type 1 this included people with a hypocretin-1 level between 110 and 150, or people with typical cataplexy and an MSLT sleep latency between eight and 12 minutes or just one SOREMP. For people with narcolepsy type 2 and idiopathic hypersomnia this included people with a sleep latency between eight and 12 minutes. The distribution of people with a clinical diagnosis across the groups is shown in Supplementary Table 1. Supplementary Table 1: Samples excluding clinical diagnoses Group Total sample (N) Sample excluding clinical diagnoses (N) Narcolepsy type 1 290 258 Narcolepsy type 2 28 21 Idiopathic hypersomnia 87 57 N reflects the available data for the corresponding variable. Immunological events before narcolepsy type 1 onset (excluding people with a clinical diagnosis) Infection and/or influenza vaccination history was known in 176 individuals with narcolepsy type 1, of whom the infection history was known in 136 (Supplementary Figure 1A) and the influenza vaccination history in 132 (Supplementary Figure 1B). An infection and/or influenza vaccination were reported before developing narcolepsy type 1 in 77/176 individuals (43.8%). Among the people with narcolepsy type 1, 12 reported an infection and influenza vaccination before the onset of their hypersomnolence disorder. These individuals were included in Supplementary Figure 1 in the immunological event closest to their onset of narcolepsy type 1 symptoms (for four people, this was an infection and for five people, influenza vaccination). In three people, the infection and influenza vaccination were similarly close to narcolepsy type 1 onset and these individuals was included in both groups. 4
RkJQdWJsaXNoZXIy MjY0ODMw